SHIRLEY, N.Y., July 8, 2020 /PRNewswire-PRWeb/ — Following up the initial release of NEW Advantage BX software in January, Biodex Medical Systems, Inc. has enhanced the software with new reporting capabilities focused on getting injured athletes back in play safely. The first-ever Return-to-Play report displays isokinetic test results with clear pass/fail to aid in communication with physicians and athletes throughout the athlete’s recovery.
The new report is a response to the recent resurgence of isokinetic strength testing after ACL reconstruction. Research has shown strength symmetry and balanced hamstring to quadriceps ratios are major components of return-to-play criteria to reduce reinjury after ACL-R. Other criteria include functional test symmetry, agility testing, psychological readiness, and time.
Backed by current research and supported by a panel of experts, the report is designed to give patients and referring physicians the added confidence they are ready to return to play.
“The high failure of ACL reconstruction and the debate of when to return to play is a very active conversation throughout the world,” states Ed Behan, Sr. Vice President, Market Development at Biodex. “The new report is a first, and we’re grateful to have had so many key opinion leaders participating in its creation.”
Live chat with Biodex representatives during the NATA Athletic Trainers’ Virtual Convention, July 13-15, or visit https://www.biodex.com/s4bx for more information.
About Biodex Medical Systems, Inc.
Biodex Medical Systems, Inc. uses science and technology to drive treatment innovation across physical medicine, nuclear medicine and medical imaging categories. With a history of manufacturing and engineering excellence that spans more than 60 years, the Biodex mission is to provide innovative solutions and customer-driven support to medical facilities and wellness centers around the globe. For more information, visit http://www.biodex.com.
SOURCE Biodex Medical Systems, Inc.
GENEVA, SWITZERLAND / ACCESS Newswire / December 15, 2025 / MindMaze Therapeutics Holding SA (SIX:MMTX)…
Milestone enables GMP manufacturing to accelerate clinical trials and transform global vaccine delivery BRISBANE, Australia…
BEIJING, Dec. 14, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading…
12 Month Timeline - How Cannabis Rescheduling Actually Takes EffectAnnouncementPresident signals intent or issues executive…
First FDA approved treatment in 30+ years for more than 2 million Americans with PSVT Novel…
NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- TrialWire®, the industry’s fastest, intelligent patient recruitment…